| EGFR-directed monoclonal antibodies in non-small cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 23300028 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Several monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been evaluated in patients with non-small cell lung cancer (NSCLC). Cetuximab, a chimeric monoclonal antibody, has been studied in combination with first-line chemotherapy in phase II and two phase III trials in patients with advanced NSCLC. The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. Cetuximab added to carboplatin/paclitaxel failed to improve progression-free survival in the BMS099 phase III trial. However, a meta-analysis of four randomized trials confirmed a significant survival benefit for platinum-based chemotherapy plus cetuximab compared to chemotherapy alone. High EGFR expression of tumor cells was then shown to predict the benefit of cetuximab, whereas KRAS mutations and EGFR fluorescent in situ hybridization analysis were without predictive value. Matuzumab and panitumumab have also been studied in phase II trials. Necitumumab, a fully human monoclonal antibody, is currently evaluated in combination with chemotherapy in two phase III trials in patients with advanced NSCLC. Cetuximab is also studied in combination with chemoradiotherapy in patients with locally advanced NSCLC. |
| | |
Authors:
|
Robert Pirker |
Related Documents
:
|
23423768 - Egfr-targeted therapy for non-small cell lung cancer: focus on egfr oncogenic mutation. 217528 - Primary oat cell carcinoma of the larynx: a case report and review of the literature. 23649448 - Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: a... 23054908 - Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for... 17309608 - The predicted probability of having positive non-sentinel lymph nodes in patients who r... 8541098 - Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-9 |
Journal Detail:
|
Title: Targeted oncology Volume: - ISSN: 1776-260X ISO Abbreviation: Target Oncol Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101270595 Medline TA: Target Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria, robert.pirker@meduniwien.ac.at. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predicting the Impact of Single-Nucleotide Polymorphisms in CDK2-Flavopiridol Complex by Molecular D...
Next Document: The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to sec...